Aligning MedTech Reimbursement and Go-to-Market in France: Field-Proven Insights

Most MedTech companies don’t fail in France because of reimbursement. They fail because they treat reimbursement and go-to-market as two separate strategies. In France, that mistake costs years.

Based on more than 25 years of MedTech leadership and hands-on experience supporting international companies entering the French market, one lesson stands out: reimbursement is not the outcome of your go-to-market strategy. It is one of its starting points. The companies that succeed in France are those that align both from day one.

France: More Than a Market – A System to Understand

France is often described as a complex MedTech market. That is true—but complexity is not the real challenge.
The real challenge is that France operates as a highly integrated healthcare system, where access depends on far more than clinical performance.
Reimbursement decisions are made centrally, following evaluation by the French National Authority for Health (HAS). Once obtained, they provide nationwide access across public and private hospitals.
But reimbursement in France is not just about clinical evidence.
Decision-makers want to understand:

• Where the technology fits within the patient pathway
• Which patient populations benefit most
• How it performs in real-world clinical settings
• Whether outcomes are reproducible beyond controlled trials
• What organizational and economic impact it creates

In other words: France forces companies to think beyond product performance.
It forces alignment across clinical practice, hospital economics, physician adoption, and national healthcare priorities.
Companies that start preparing for this only after CE marking are already behind.

The Core Mistake: Separating Reimbursement and Go-to-Market

Many MedTech companies follow a sequential logic: Obtain CE marking, launch commercially, start working on reimbursement.

At first glance, this seems reasonable.
In practice, it is one of the most expensive strategic mistakes.
This sequential approach doesn’t just create inefficiencies. It fundamentally weakens the reimbursement case.
By the time companies engage with French authorities:

• critical evidence was never generated
• relevant endpoints were not captured
• key stakeholders were not involved early enough
• early clinical use cases are missing

At that point, recovery becomes expensive — or impossible.
The most successful companies take a different approach:
They design reimbursement and go-to-market as one integrated strategy from the start.

Go-to-Market as a Reimbursement Engine

A well-executed go-to-market strategy is not just about sales. In France, it is a core mechanism to build your future reimbursement case.

Developing Reference Centers

Reference centers are often the foundation of successful market entry. They do more than enable first commercial use:

• They generate early clinical experience
• They refine patient selection and treatment protocols
• They produce real-world insights on outcomes and workflows

Most importantly, they create credibility.
In France, the absence of early clinical use is often interpreted as a signal that a technology does not address a meaningful unmet need. Reference centers do not just support adoption—they validate relevance.

Building a Community of Early Adopters

Early adopters are not simply first users. They are co-creators of your value proposition.
They help to:

• identify real-world benefits and limitations
• define practical use cases
• surface implementation challenges
• build confidence among peers

Over time, they often become ambassadors. In several successful reimbursement projects, early adopters played a decisive role—contributing to scientific communications, influencing peers, and supporting formal recognition by academic or scientific societies. This type of professional endorsement can significantly strengthen a reimbursement dossier.

Generating Real-World Evidence

Real-world evidence (RWE) is no longer optional. The European Medical Device Regulation (MDR) places continuous clinical evaluation and post-market follow-up at the center of evidence generation. In France, RWE is particularly valuable because:

• many technologies are operator-dependent
• clinical practice varies across institutions
• organizational impact matters

Randomized trials remain essential. But RWE provides something equally critical:

• reproducibility
• learning curves
• long-term outcomes
• real-life patient selection
• operational impact

It acts as a bridge between clinical research and reimbursement.
Companies that invest early in local data generation gain a decisive advantage. Those who delay often realize too late that the required evidence was never collected.

Understanding Coding and Hospital Funding

Another common mistake is treating coding and funding mechanisms as a “later-stage” topic.
In reality, they influence adoption from day one.
Procedure coding, hospital financing structures, and budget impact considerations shape:

• how hospitals can use the technology
• whether adoption is financially viable
• what data needs to be captured early

A strong coding strategy is not a technical detail. It is a strategic enabler of both adoption and reimbursement.

Four Questions That Define Success in France

In practice, every successful market entry starts with four fundamental questions:

• Which reimbursement pathway is realistically achievable?
• Which evidence gaps must be addressed—and when?
• Which centers should become your reference sites?
• Which data must be captured from the first patient onward?

These are not reimbursement questions alone. They define your entire go-to-market architecture.

France as a Strategic Learning Environment

Many companies see France as a barrier. In reality, it is one of the most valuable learning environments in Europe.
Entering France is not just a commercial exercise. It is a transformation of how companies think about evidence generation, stakeholder engagement, clinical value, ecosystem alignment.

Companies that succeed in France articulate a clear value proposition, generate meaningful real-world data, build strong clinical networks and engage early with the right stakeholders. This discipline creates value far beyond France.
The lessons learned translate directly into stronger positioning across other European markets.

Conclusion

Reimbursement and go-to-market in France should never be treated as separate projects. The strongest reimbursement cases are built through deliberate field execution. And the most effective commercial strategies are guided by reimbursement requirements from the start. Reference centers, early adopters, real-world evidence, and coding strategies are not just commercial tools.
They are the building blocks of market access. Companies that integrate both dimensions early create faster adoption, stronger reimbursement outcomes and more sustainable growth.

One lesson is universal: Reimbursement and go-to-market create far more value when they are designed together.
In France, reimbursement is not the end of the journey. It is where the strategy begins.

About the author: Emmanuel Deschamps is CEO of Caredis, an independent consulting firm specialized in MedTech reimbursement strategy and go-to-market execution in France.With more than 25 years of experience across pharmaceutical and medical technology industries, he has held senior leadership positions at Pfizer, Medtronic, Edwards Lifesciences, Becton Dickinson, and Abiomed. Today, he supports international MedTech and Digital Health companies in building integrated market entry strategies—combining reimbursement, clinical adoption, and commercial scale-up from the outset.